GetTopicDetailResponse(id=3a0212362e6b, topicName=奧雷巴替尼, introduction=, content=急性淋巴細(xì)胞白血病 奧雷巴替尼, image=null, comments=0, allHits=351, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Jan 23 15:52:06 CST 2025, time=2025-01-23, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=120041, tagList=[TagDto(tagId=120041, tagName=奧雷巴替尼)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2276716, encodeId=657422e6716bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a> <a href='/topic/show?id=3a0212362e6b' target=_blank style='color:#2F92EE;'>#奧雷巴替尼#</a>, objectTitle=【AJH】奧雷巴替尼聯(lián)合奧加伊妥珠單抗治療成人Ph陽性ALL, objectType=article, longId=891012, objectId=b2908910126c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241122/1732253316439_8538692.png, objectUrl=/article/show_article.do?id=b2908910126c, replyNumber=0, likeNumber=17, createdTime=2025-08-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b2908910126c, moduleTitle=【AJH】奧雷巴替尼聯(lián)合奧加伊妥珠單抗治療成人Ph陽性ALL, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b2908910126c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2272270, encodeId=f54a22e227070, content=<a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細(xì)胞白血病#</a> <a href='/topic/show?id=3a0212362e6b' target=_blank style='color:#2F92EE;'>#奧雷巴替尼#</a>, objectTitle=【Leukemia】奧雷巴替尼聯(lián)合維奈克拉和低強(qiáng)度化療治療成人新診斷Ph+ ALL的2期研究, objectType=article, longId=885572, objectId=74a78855e21e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301007/1696677796117_2570354.jpg, objectUrl=/article/show_article.do?id=74a78855e21e, replyNumber=0, likeNumber=28, createdTime=2025-07-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=74a78855e21e, moduleTitle=【Leukemia】奧雷巴替尼聯(lián)合維奈克拉和低強(qiáng)度化療治療成人新診斷Ph+ ALL的2期研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=74a78855e21e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2265202, encodeId=c1a92265202b4, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=3a0212362e6b' target=_blank style='color:#2F92EE;'>#奧雷巴替尼#</a>, objectTitle=中國多中心研究探索奧雷巴替尼治療慢性期CML的優(yōu)化劑量, objectType=article, longId=877556, objectId=a69b8e755640, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240508/1715158312120_92910.png, objectUrl=/article/show_article.do?id=a69b8e755640, replyNumber=0, likeNumber=28, createdTime=2025-05-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a69b8e755640, moduleTitle=中國多中心研究探索奧雷巴替尼治療慢性期CML的優(yōu)化劑量, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a69b8e755640)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2249329, encodeId=2c48224932965, content=<a href='/topic/show?id=994952328d2' target=_blank style='color:#2F92EE;'>#急性淋巴細(xì)胞白血病#</a> <a href='/topic/show?id=3a0212362e6b' target=_blank style='color:#2F92EE;'>#奧雷巴替尼#</a>, objectTitle=Ph+ ALL異基因移植后奧雷巴替尼維持治療的北京大學(xué)人民醫(yī)院回顧性研究, objectType=article, longId=860621, objectId=819c86062191, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250123/1737595810846_8538692.jpg, objectUrl=/article/show_article.do?id=819c86062191, replyNumber=0, likeNumber=46, createdTime=2025-01-23, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=819c86062191, moduleTitle=Ph+ ALL異基因移植后奧雷巴替尼維持治療的北京大學(xué)人民醫(yī)院回顧性研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=819c86062191)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-01-23發(fā)表于陜西省
